121 related articles for article (PubMed ID: 15830571)
1. Clinical benefit of intermittent administration of imatinib in a patient with metastatic gastrointestinal stromal tumour.
Morabito A; Longo R; Carillio G; Bonginelli P; Vitale S; Gasparini G
Clin Oncol (R Coll Radiol); 2005 Apr; 17(2):96-7. PubMed ID: 15830571
[TBL] [Abstract][Full Text] [Related]
2. [Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].
Larsen JB
Ugeskr Laeger; 2003 Sep; 165(37):3503-7. PubMed ID: 14531349
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.
Yeh CN; Fu CJ; Yen TC; Chiang KC; Jan YY; Chen MF
J Clin Oncol; 2013 Jun; 31(16):e248-50. PubMed ID: 23569321
[No Abstract] [Full Text] [Related]
4. [Effect of imatinib treatment of gastrointestinal stromal tumors].
Eckhardt S; Pápai Z; Bodoky G; Horti J; Tamás K; Nagy T; Orosz Z; Sápi Z; Gödény M; Jakab K; Esik O; Trón L; Besznyák I
Orv Hetil; 2003 Nov; 144(45):2207-12. PubMed ID: 14686005
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
Joensuu H
Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
8. Familial and multiple gastrointestinal stromal tumors with fair response to a half-dose of imatinib.
Bamba S; Hirota S; Inatomi O; Ban H; Nishimura T; Shioya M; Imaeda H; Nishida A; Sasaki M; Murata S; Andoh A
Intern Med; 2015; 54(7):759-64. PubMed ID: 25832938
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Le Cesne A; Ray-Coquard I; Bui BN; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Cioffi A; Emile JF; Chabaud S; Pérol D; Blay JY;
Lancet Oncol; 2010 Oct; 11(10):942-9. PubMed ID: 20864406
[TBL] [Abstract][Full Text] [Related]
10. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
11. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
Jamali FR; Darwiche SS; El-Kinge N; Tawil A; Soweid AM
Oncologist; 2007 Apr; 12(4):438-42. PubMed ID: 17470686
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of gastrointestinal stromal tumours.
Eisenberg BL; von Mehren M
Expert Opin Pharmacother; 2003 Jun; 4(6):869-74. PubMed ID: 12783584
[TBL] [Abstract][Full Text] [Related]
13. Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts.
Silberman S; Joensuu H
Eur J Cancer; 2002 Sep; 38 Suppl 5():S66-9. PubMed ID: 12528775
[TBL] [Abstract][Full Text] [Related]
14. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
Hamza I; Gaies E; Kastalli S; Daghfous R; El Aidli S
Therapie; 2014; 69(3):245-7. PubMed ID: 24934821
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
Steinert DM; McAuliffe JC; Trent JC
Expert Opin Pharmacother; 2005 Jan; 6(1):105-13. PubMed ID: 15709888
[TBL] [Abstract][Full Text] [Related]
16. Intolerance to imatinib in gastrointestinal stromal tumors: a case report and a review of literature.
Akasbi Y; Arifi S; Brahmi SA; El Mrabet FZ; Mellas N; Mernisi FZ; El Mesbahi O
J Gastrointest Cancer; 2014 Dec; 45 Suppl 1():71-3. PubMed ID: 24006243
[No Abstract] [Full Text] [Related]
17. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
18. [Gastrointestinal stromal tumours bigger than 20 cm: experience with imatinib chemotherapy in neoadjuvant intention].
Girotti P; Rolinger J; Kopp HG; Königsrainer A; Ladurner R
Z Gastroenterol; 2014 Jan; 52(1):50-4. PubMed ID: 24420799
[TBL] [Abstract][Full Text] [Related]
19. Imatinib treatment of metastatic GIST: don't stop (believing).
Heinrich MC
Lancet Oncol; 2010 Oct; 11(10):910-1. PubMed ID: 20864404
[No Abstract] [Full Text] [Related]
20. Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
Durosinmi MA; Salawu L; Lawal OO; Ojo OS; Alatishe OI; Oyekunle AA; Bolarinwa RA; Adisa AO; Badmos K; Anomneze EE; Ayansanwo AO
Afr J Med Med Sci; 2013 Dec; 42(4):325-32. PubMed ID: 24839736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
